ARAY Stock News 8.25 05/13/2014 14:34:40 Accuray Incorporated

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 3:34 PM

Accuray Incorporated (ARAY) 8.25 $ARAY

Echo Therapeutics Q1 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 8:20AM CDT
Following the earnings release, shares of Echo Therapeutics, Inc. (ECTE) crashed 32.6% to close at $2.07 till the last reported session as the company continues to make losses.

Health Care Sector Stocks Coverage -- Research on Accuray, Varian Medical Systems, Intuitive Surgical, and Edwards Lifesciences
PR Newswire - Mon May 12, 11:30AM CDT
The markets on Friday, May 09, 2014 ended on a positive note as the S&P 500 finished the session 0.15% higher at 1,878.48, and the NASDAQ Composite closed at 4,071.87, up 0.50%. The Dow Jones Industrial Average finished at 16,583.34, up 0.20%. The gains were broad based as six out of ten sectors ended in positive. During the session gains in the Consumer Discretionary, Health Care and Consumer Staples sectors positively impacted the broader market, while some retraction came in from Materials, Financials, and Energy sectors. The S&P 500 Health Care Sector Index closed the day at 668.35, up 0.58%, with the index also advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Accuray Inc. (NASDAQ: ARAY), Varian Medical Systems Inc. (NYSE: VAR), Intuitive Surgical Inc. (NASDAQ: ISRG) and Edwards Lifesciences Corporation (NYSE: EW). Free technical research on ARAY, VAR, ISRG and EW can be downloaded upon signing up at:

Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 11:10AM CDT
Sirona Dental Systems, Inc. (SIRO) anticipates adjusted earnings in the range of $3.60 to $3.70 per share for fiscal 2014, implying a growth of 6-9%.

Thoratec Beats on Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:43AM CDT
Since the earnings announcement, shares of Thoratec Corporation (THOR) dipped 3.7%.

ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
ArthroCare Corp.'s (ARTC) total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.

Falling Earnings Estimates Signal Weakness Ahead for ABIOMED (ABMD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:52AM CDT
ABIOMED has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.

Abiomed Sees Flat Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 9:00AM CDT
For fiscal 2015, Abiomed (ABMD) forecasted revenues between $205 and $212 million for the year.

Mindray Medical Misses on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:54PM CDT
Mindray Medical International Limited (MR) continues to expect 2014 net revenues to grow at least 15% over 2013.

Mindray Medical International Limited (MR) Crumbles: Stock Falls by 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
Mindray has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

JOSHUA LEVINE of Accuray Incorporated (ARAY)-Nasdaq bought Shares of ARAY
M2 - Wed May 07, 6:57AM CDT
Reported by InsiderCow.com at 2014-05-06 12:53:17 ET

Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:10AM CDT
Following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.

DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:32AM CDT
DexCom's (DXCM) total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million.

Omnicell Drops Despite Q1 Earnings & Revs Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:20AM CDT
Omnicell, Inc. (OMCL) reported first-quarter 2014 adjusted EPS of 19 cents.

Accuray Signs Three-Year Contract with Amerinet
PR Newswire - Tue May 06, 7:30AM CDT
Accuray Incorporated (Nasdaq: ARAY) announced today that it has signed a new three-year contract with Amerinet on the CyberKnife® M6(TM) and TomoTherapy® H(TM) product portfolio.

Q4 Earnings Beat, Revs Miss Ests at PetMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:19AM CDT
PetMed Express' (PETS) EPS of 23 cents in the fourth quarter of fiscal 2014 came in 2 cents ahead of the Zacks Consensus Estimate.

Hologic Up on Q2 Earnings Beat & Raised Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:50AM CDT
Shares of Hologic Inc. (HOLX) surged more than 8% to $22.74 after market-close on May 2 since the release of its second-quarter fiscal 2014 results.

Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:22AM CDT
For 2014, Masimo Corporation (MASI) expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million.

Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:20AM CDT
Accuray Incorporated (ARAY) raised its total revenue guidance for fiscal 2014 to a range of $355 to $365 million from the previous range of $340 to $350 million.

Why Accuray (ARAY) Stock Is Down Today
at The Street - Thu May 01, 12:36PM CDT
Accuray (ARAY) shares are down despite beating analysts third quarter earnings and revenue guidance, and increasing its own full year guidance.

Accuray Reports Financial Results for Third Quarter of Fiscal Year 2014
GlobeNewswire - Wed Apr 30, 3:12PM CDT
Achieves Positive Cash Flow on Strong Revenue Growth

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...